Sickle Cell Disease (SCD) is a debilitating blood disorder with high mortality rates, yet to date only a single therapy for the disease has been approved by the FDA. Markedly, improved insight into the complex pathophysiology of SCD has led to the recent development of diverse approaches for treatment, including inhibition of hemoglobin polymerization, prevention and treatment of vaso-occlusive events, and disease corrective gene therapy approaches. This symposium will discuss these recent developments highlighting key biological mechanisms of disease and reviewing relevant clinical science around SCD, while underscoring the importance of the patient experience.
Call for Abstracts
Abstract submissions are invited for a poster session, and two abstracts will be selected for short talks. For complete submission instructions, please visit our online portal. The deadline for abstract submission is August 25, 2017.
|Member (Student / Postdoc / Fellow)
|Nonmember (Student / Postdoc / Fellow)
The Biochemical Pharmacology Discussion Group is proudly supported by:
ACS New York Section